Last reviewed · How we verify
Maxalt
At a glance
| Generic name | Maxalt |
|---|---|
| Also known as | rizatriptan |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache (PHASE4)
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maxalt CI brief — competitive landscape report
- Maxalt updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI